Insider Buying: Sensus Healthcare (NASDAQ:SRTS) Director Buys 10,925 Shares

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta purchased 10,925 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were acquired at an average price of $3.18 per share, with a total value of $34,741.50. Following the purchase, the director owned 229,943 shares of the company’s stock, valued at approximately $731,218.74. This trade represents a 4.99% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Eric Sachetta also recently made the following trade(s):

• On Wednesday, August 26th, Eric Sachetta acquired 9,708 shares of Sensus Healthcare stock. The stock was bought at an average price of $3.29 per share, for a total transaction of $31,939.32.
• On Monday, August 24th, Eric Sachetta bought 34,697 shares of Sensus Healthcare stock. The stock was bought at an average cost of $3.25 per share, with a total value of $112,765.25.

Sensus Healthcare Price Performance

Shares of Sensus Healthcare stock traded up $0.13 during midday trading on Friday, hitting $3.50. 62,187 shares of the company were exchanged, compared to its average volume of 64,747. The firm has a 50 day simple moving average of $3.04 and a 200-day simple moving average of $3.52. The firm has a market cap of $57.61 million, a P/E ratio of -3.72 and a beta of 1.10. Sensus Healthcare, Inc. has a 52 week low of $2.66 and a 52 week high of $5.49.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%. The company had revenue of $2.29 million during the quarter, compared to the consensus estimate of $4.60 million.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Alliance Global Partners reissued a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th. Wall Street Zen lowered shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Lake Street Capital cut their target price on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Weiss Ratings downgraded Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Finally, Citigroup restated a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $5.83.

Institutional Investors Weigh In On Sensus Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. EP Wealth Advisors LLC bought a new position in shares of Sensus Healthcare in the second quarter worth about $49,000. XTX Topco Ltd acquired a new stake in shares of Sensus Healthcare in the fourth quarter valued at approximately $77,000. Jane Street Group LLC bought a new position in Sensus Healthcare in the 4th quarter worth approximately $79,000. Ingalls & Snyder LLC acquired a new position in Sensus Healthcare during the 4th quarter worth $219,000. Finally, BlackRock Inc. bought a new position in Sensus Healthcare in the 2nd quarter valued at $252,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.